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A b s t r a c t
Malignant tumours in pregnant women are rare. The terms ‘gestational breast
cancer (GBC)’ and ‘pregnancy-associated breast cancer’ are given to breast cancer
cases diagnosed during pregnancy and up to one year post-partum. Treatment
methods, as well as treatment onset and time of pregnancy termination, remain
controversial. We describe two fatal cases of GBC in multiparous women over 
35 years of age. The first patient was a thirty-seven year old woman with breast
cancer diagnosed in the 26th week of gestation treated with surgery and
postoperative chemotherapy. The second case was a thirty-nine year old pregnant
woman with primary inoperable breast cancer treated with chemotherapy since
the 24th week of gestation. We conclude that breast cancer during pregnancy
requires a multidisciplinary approach to ensure optimal care for both the mother
and the baby. Prognosis in GBC similarly to breast cancer in non-pregnant women
depends mainly on the stage of the disease at the time of diagnosis. 
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Introduction
Malignant tumours in pregnant women are rare. Leukaemias and
lymphomas are the most common malignant neoplasms in pregnant
women under 25 years of age [1, 2]. In older patients breast cancer occurs
predominantly and it is diagnosed in 1/100 000 pregnancies [3]. Incidence
of breast cancer increases with age of pregnant woman [2, 4]. Breast cancer
diagnosed during pregnancy and up to one year post-partum is known as
gestational breast cancer (GBC) [1, 5]. According to Jassem [5] and Wong
et al. [6] GBC is diagnosed in 10-40/100 000 women, which means 2-3%
of all breast cancers. Similar frequency of this cancer, e.g. 0.2-3.8%, was
described by Ring et al. [4].
Because of physiological changes in pregnant women, including
morphological and functional changes in the mammary gland, detection
1Department of Surgical Oncology, Chair of Oncology, Medical University of Lodz, 
Lodz, Poland
2Palliative Care Unit, Chair of Oncology, Medical University of Lodz, Lodz, Poland
3Department of Chemotherapy of Neoplasms, Chair of Oncology, Medical University 
of Lodz, Lodz, Poland
4Department of Gynaecological Oncology, Chair of Oncology, Medical University of Lodz,
Lodz, Poland
5Department of Pathology, Chair of Oncology, Medical University of Lodz, Lodz, Poland
Submitted: 13 November 2007
Accepted: 3 February 2008
Arch Med Sci 2008; 4, 2: 204–207
Copyright © 2008 Termedia & Banach
Corresponding author:
Leszek Gottwald, MD, PhD
Palliative Care Unit




Phone: +48 42 689 54 81
Fax: +48 42 689 54 22
E-mail: lgottwald@wp.pl
Case report
Arch Med Sci 2, June / 2008 205
of breast tumours is difficult [6]. A multidisciplinary
approach is needed involving a gynaecologist, 
a medical oncologist and a surgeon. Treatment
methods, as well as treatment onset and time of
pregnancy termination (if necessary), remain
controversial [1]. 
The aim of the study was to analyze two cases
of gestational breast cancer and to review the




Two cases of pregnant women with breast cancer
diagnosed during pregnancy were analyzed. Patients
were treated in the Centre of Oncology, Medical
University of Lodz during 2002-2004. Clinical signs
and symptoms in patients, diagnostics, treatment
and its outcome were analyzed.
Thirty-seven year old multipara, with a negative
family history of malignancies, previously not
diagnosed with breast diseases, detected a painless
lump in her left breast during self examination in
February, 2002. The gynaecologist did not confirm
any diagnosis of breast tumour. Two months later
the patient became pregnant with twins. Her
pregnancy was confirmed in the 25th week of
gestation. At the same time a tumour in her left
breast was diagnosed. Ultrasound breast scan,
performed in the 26th week of gestation, revealed
a tumour 2 cm in diameter in the upper external
quadrant of the left breast, 6 cm from the nipple;
axillary revealed cancer cells. The patient was
qualified for Madden type modified radical
mastectomy and she was operated on in the 27th
week of gestation. The histological examination
disclosed infiltrating ductal carcinoma G3, pT1N1Mx.
One metastatic lymph node was found with
infiltration of its capsule out of 3 axillary nodes
resected. Oestrogen receptors [ER], progesterone
receptors [PR] and HER2 receptors were absent. The
pregnancy was terminated by caesarean section in
the 32nd week of gestation. She delivered healthy
twins – a female newborn of 1550 g and a male of
2200 g. Seven days after delivery adjuvant
chemotherapy was administered. Clinical and
additional examination revealed no distant
metastases. The patient was treated with 6 cycles
of doxorubicin (adriblastin) and cyclophosphamide.
After 14 months abdominal ultrasound revealed
numerous liver metastases. The patient underwent
further treatment with cytostatics – 5 cycles of
Taxotere and methotrexate – but the clinical state
deteriorated, which led to chemotherapy withdrawal.
Unfortunately, after 1 cycle of methotrexate and
fluorouracil (second line treatment) progression of
the disease was observed, and the patient died.
Case II
A 39-year old multipara, with a negative family
history of malignancies, in the 16th week of
gestation during vaginal examination was
diagnosed, and the diagnosis was confirmed by
ultrasound examination. Tumour in the right breast
was detected by the same physician during the first
visit. Tumour with ulceration and decay
encompassed almost the whole breast (diameter
about 10 cm). The patient was sent to the oncology
centre for further evaluation and treatment. 
The histopathological examination of a surgical
biopsy specimen confirmed breast cancer
(infiltrating ductal cancer, ER/-/, PR/-/, HER2/3+/).
Because of the primary inoperable status of the
disease the patient was qualified for chemotherapy.
Taking into consideration the advanced stage of
pregnancy (24th week), the decision to continue it
was made. The patient received doxorubicin
monotherapy. After 2 cycles chest radiography
showed lung metastases. After informed written
consent, termination of the pregnancy by caesarean
section was recommended (an additional indication
for caesarean delivery was transverse fetus
presentation). The caesarean section was performed
in the 34th week of gestation. A male newborn of
53 cm, 1900 g, 8 Apgar score was delivered. During
laparotomy bilateral ovariectomy was performed.
No peritoneal involvement or visceral metastases
were noted. Neither ovary was macroscopically
suspected but histopathological investigation
revealed foci of breast cancer metastases. After 
a two-week postpartum period, the patient received
cyclophosphamide, methotrexate, and 5-fluorouracil
regimen in the Department of Oncology. No
remission after chemotherapy was achieved and
the patient died one year later.
Discussion
There is disagreement in worldwide literature
concerning the influence of pregnancy on the
incidence and course of breast cancer. According to
Kroman et al. [7] high oestrogen concentration
during pregnancy can increase the growth of breast
cancer [7]. However, other studies did not show that
in breast cancer patients pregnancy and lactation
have a significant impact on poor outcome, and
prognosis is similar for pregnant and non-pregnant
women depending on the stage of disease [3, 5, 6].
Many studies have shown that in pregnant breast
cancer patients the percentage of advanced stages
of disease at the time of diagnosis is higher than
in the remaining group of breast cancer patients 
[1, 6]. It has also been shown that early breast
cancer is 2.5 times more rarely diagnosed in
pregnant patients compared to other women.
These differences can be explained by physiological
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changes in the breast during pregnancy (enlargement,
angiogenesis), which make physical examination
less sensitive, and by complete lack of self-
examinations of pregnant women as well as low
attention to proper breast examination given by
gynaecologists [2].
Regular self-examination performed by women
has a significant influence on early detection of
breast tumours. Additionally, gynaecologists are
required to conduct the breast examination in
pregnant women [5]. When a breast tumour is
detected in pregnant or post-partum women, the
diagnostic tools should be applied as in non-pregnant
patients [2-4, 6, 8]. Ultrasonography, mammography
(during breast feeding) and biopsy should be done
to establish precise diagnosis and stage of disease
[1-3, 9]. According to the German Breast Group (GBG-
29), sensitivity of mammography in such cases is
about 68%, while sensitivity of ultrasonography is
93% [2]. Additionally, excluding computer tomography
(CT), the remaining radiological investigations, e.g.
chest X-ray with abdominal shielding, liver ultrasound
and non-contrast magnetic resonance imaging (MRI)
(especially after the first trimester), should also be
done [6].
The optimal treatment of GBC patients is still 
a dilemma for the gynaecologist, surgeon and
oncologist [1, 2, 4, 8, 10, 11]. Proper standards of
treatment of such patients are needed. According to
MD Anderson Cancer Center protocols, if early breast
cancer is diagnosed in the first trimester of pregnancy
(by the 16th week of gestation) abortion should be
considered [8]. If pregnancy is continued, the risk of
poor outcome is higher, because adjuvant
chemotherapy cannot be administrated in the early
phase of gestation [4, 12]. If abortion is performed,
chemotherapy should be given according to general
standards for non-pregnant women with breast cancer
(MD Cancer Center and GBG-29 recommendations)
[2, 8, 12]. If pregnancy is continued, radical modified
mastectomy should be performed in the first trimester
as a treatment of choice [6, 13, 14]. Most cancer
centres do not perform breast conserving surgery,
because it should be followed by radiotherapy, which
is contraindicated during pregnancy irrespective of
its phase [6, 13, 14]. However, surgical treatment is
connected with the risk of complications such as
wound infection, cellulitis or erysipelas, which is
similar for pregnant and non-pregnant women [15].
Radiotherapy should be postponed to the second or
third trimester of pregnancy because of its teratogenic
potential [11, 13].
To avoid axillary node dissection and reduce
postoperative complications such as arm oedema, 
a sentinel node biopsy (SNB) can be performed to
assess the nodal staging in early breast cancer
patients. The sentinel node is the first lymph node
on the way of lymphatic flow from the primary
tumour. SNB is usually performed using a radiotracer.
To improve the identification rate, this technique is
often combined with blue dye mapping. Previously
pregnancy was a contraindication to performing SNB.
Taking into consideration the low risk of fetus
irradiation, several studies have described the use of
radiotracer technique of SNB in pregnant breast
cancer patients [16-18]. Further prospective studies
have already been  launched to assess the safety and
utility of SNB in these patients [18]. However, blue
dye technique is still contraindicated in pregnant
patients [16-18]. Breast cancer prognostic factors for
pregnant and non-pregnant women are similar and
include: clinical staging (according to TNM system),
age, grading (G), the number of metastatic nodes,
expression of oestrogen (ER) and progesterone (PgR)
receptors, and expression of human epidermal
growth factor receptor (HER-2) [6, 14, 16].
It was also observed that chemotherapy given
during pregnancy may cause spontaneous abortion
and increased risk of congenital malformations in 
7.5-17% of neonates. Adjuvant and neoadjuvant
chemotherapy is not likely to influence normal
development of the fetus [1, 6, 11, 12, 19]. According
to Gwyn et al. [8], Hahn et al. [11], and Bodner-Adler
et al. [1], patients with GBC in the 2nd and 3rd trimester
of pregnancy can be treated with doxorubicin 
(50 mg/m2 per 72 hours), cyclophosphamide 
(500 mg/m2 per 1 hour) and 5-fluorouracile 
(500 mg/m2 within 1-4 days). Ring et al. [4] also
describe a group of patients treated with CMF
regimen. In the French National Survey conducted by
Giacalone et al., docetaxel, paclitaxel and vinorelbine
chemotherapy was also administrated to pregnant
women [10].
Time and mode of delivery are a compromise
between the risk of less aggressive treatment of
cancerous disease and the risk of preterm delivery
with its complications [4]. There are some reports
demonstrating an increased number of peripartum
complications such as pre-eclampsia or fetal
hypotrophy in breast cancer pregnancies [4], but not
all studies confirmed these data [8, 11, 13]. In pregnant
women with breast cancer treated in the MD
Anderson Cancer Center, the number of caesarean
sections and of vaginal deliveries were similar [8]. We
share the opinion that pregnancy with GBC should
be terminated after the 33rd week of gestation.
However, Epstein et al. [12] recommend termination
in the 36th week of gestation. In the presented cases
children were born by caesarean section in the 32nd
and 34th week of gestation respectively. Maternal and
neonatal sepsis and haemorrhage are potential
complications of myelosuppression resulting from
chemotherapy administrated in the last trimester,
which should be taken into consideration [5].
Indications for adjuvant treatment during
pregnancy and after delivery are established after
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surgery and histopathological findings. After delivery
chemotherapy as well as radiotherapy should be
provided. Hormonal therapy should be provided only
if oestrogen and progesterone receptors are present
[2, 6, 8, 12, 14, 19]. Breast feeding is contraindicated
for women with GBC treated with radiotherapy and
hormonal therapy, since many cytotoxic drugs can
enter the breast milk [6, 9]. Therefore these patients
should be given delactating agents [6, 9].
After GBC treatment, regular check-ups in the
oncology centre for early detection of recurrence or
metastatic diseases is essential. Lambe demonstrated
that for a few years after GBC and delivery there is 
a transient increase in the risk of breast cancer
recurrence, compared to non-pregnant patients [20].
Ring et al. [4] and Wong et al. [6] showed the
necessity of regular check-ups in children born by
GBC mothers because of late side effects of exposure
to chemotherapy in utero such as: gonadal
malfunction, developmental and neurological
disorders or carcinogenic mutations. Children of
mothers treated with anthracycline can experience
cardiotoxic side effects [4]. However, all distant side
effects of chemotherapy in the 2nd and 3rd trimester
are extremely rare [11-13].
It is important to mention those patients after
gestational breast cancer treatment who are
currently contemplating future pregnancies or who
are already pregnant. There is a unanimous opinion
that pregnancy after GBC treatment has no
influence on course of disease and that history of
breast cancer has no impact on course or outcome
of future pregnancies [5, 9].
On the basis of our observations and review of
the literature we suggest that:
1. Detection of any breast tumour during pregnancy
should lead to immediate diagnostic procedures
and treatment. Fine needle aspiration biopsy should
be safety performed in this group of patients.
2. Prognosis depends mainly on the stage of the
disease at the time of diagnosis.
3. The mode of treatment should be discussed in 
a multidisciplinary team including a surgeon,
clinical oncologist and gynaecologist and should
be accepted by the patient. The main concern of
obstetricians and oncologists is the decision 
of continuation vs. termination of pregnancy if
breast cancer is diagnosed in the second
trimester of pregnancy. Decisions regarding
abortion should be based on the patient’s will
and on therapeutic necessities.
4. The treatment of choice is surgery. Radiation
therapy should be avoided because of its toxic
impact on the fetus. Chemotherapy in the
treatment of GBC is possible after the first
trimester of pregnancy. It should be administrated
according to the same principles as applied in
non-pregnant patients.
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